Covid-19: Omicron worries spur 2% slide in European stock futures

Among regional markets, UK's FTSE futures dropped 1.8%, while German DAX futures lost 2.5%

commodity derivatives
Reuters
1 min read Last Updated : Dec 20 2021 | 1:53 PM IST
European stock index futures fell 2% on Monday amid a global sell-off in equities as investors fretted over rapidly rising COVID-19 cases due to the Omicron variant and the impact of tighter pandemic-related curbs on the global economy.

Futures tracking Europe's top 50 firms slumped 2.5%, with 29,149 contracts changing hands by 0708 GMT.

Among regional markets, UK's FTSE futures dropped 1.8%, while German DAX futures lost 2.5%. Elsewhere, Asian shares fell to one-year lows and oil prices slid more than 3%.

The Netherlands imposed a lockdown on Sunday, while the prospect of tighter COVID-19 measures ahead of the Christmas and New Year holidays looms large over several European countries amid the swift spread of the Omicron variant.

Meanwhile, futures tracking the U.S. stocks benchmark S&P 500 fell 1.3% after U.S. Senator Joe Manchin, a moderate Democrat who is key to President Joe Biden's hopes of passing a $1.75 trillion domestic investment bill, said on Sunday he would not support the package.

Goldman Sachs cut U.S. real GDP forecast for the first quarter of 2022 to 2% versus 3% previously, and marginally reduced forecasts for the second and third quarters.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus Vaccine

Next Story